Eli Lilly said its weight loss drug Zepbound led to 47% greater weight reduction than rival medicine Wegovy, made by Novo ...
JetBlue Airways raised its revenue guidance for the year after bookings in November and December were higher than anticipated immediately following the U.S. presidential election. The world's ...
A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...
The bears might point out that Eli Lilly's shares still look too expensive: The company's trailing price-to-earnings (P/E) ...
Eli Lilly said Wednesday that its weight-loss medication Zepbound (tirzepatide) demonstrated superior efficacy over Novo ...
Eli Lilly (NYSE:LLY) said Wednesday its weight-loss drug Zepbound (tirzepatide) provided a 47% greater relative weight loss ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in ...
People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...
The battle between the two front runners in the vast weight loss released top-line results from the SURMOUNT-5 Phase IIIb ...